Holen Sie sich die Stockscreener-App
2.93
3.62%
-0.11
Handel nachbörslich:
2.94
0.010
+0.34%
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments - Yahoo Finance
Transcript : CytomX Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 09 - marketscreener.com
CytomX Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
CytomX Therapeutics Q1 2026 Earnings: Smaller-than-Expected Loss as Pipeline AdvancesAdjusted Earnings Analysis - newsline.com
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
CytomX gains as licensing deal with Regeneron expands - MSN
Schulhoff & Co. Inc. Acquires Shares of 374,850 CytomX Therapeutics, Inc. $CTMX - MarketBeat
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results - Yahoo Finance
Regeneron Pharmaceuticals (REGN) Valuation Check After CytomX Collaboration Expansion And Lynozyfic Trial Update - simplywall.st
CTMX: Varseta-M shows strong efficacy in late-line CRC, with pivotal trials and new partnerships advancing - TradingView
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics - Yahoo Finance
CytomX expands collaboration with Regeneron - The Pharma Letter
Regeneron deepens relationship with CytomX, adding up to $2B and eight targets - BioSpace
CytomX stock jumps on $37M Regeneron collaboration payment - Investing.com
CytomX expands Regeneron collaboration, receives $37M payment - Investing.com UK
CytomX Expands High-Value Bispecific Cancer Partnership With Regeneron - TipRanks
With billions of dollars at stake, trio of Bay Area biotechs nail down deals - The Business Journals
CytomX (NASDAQ: CTMX) adds programs, gains $37M from Regeneron - Stock Titan
CytomX Therapeutics (CTMX) Expands Collaboration with Regeneron Pharmaceuticals - GuruFocus
Why is CytomX Therapeutics stock gaining today? By Investing.com - Investing.com Canada
Why is CytomX Therapeutics stock gaining today? - Investing.com
CytomX stock jumps on $37M Regeneron collaboration payment By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
CytomX expands Regeneron collaboration, receives $37M payment By Investing.com - Investing.com South Africa
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer - The Manila Times
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - The Globe and Mail
CytomX (CTMX) Q4 2025 Earnings Transcript - AOL.com
How The CytomX Therapeutics (CTMX) Story Is Shifting With New Colorectal Cancer Data And Risks - Yahoo Finance
CytomX Therapeutics (CTMX) Holds Steady Near Resistance After 3.25% GainWyckoff Distribution - newsline.com
CytomX Therapeutics: Cashed Up With Catalysts Ahead (NASDAQ:CTMX) - Seeking Alpha
CytomX Therapeutics (CTMX) Holds Steady Near Support – Key Levels to WatchMACD Signal Stocks - The Legal Advocate
Wolfe Research Initiates Coverage of CytomX Therapeutics (CTMX) with Outperform - Insider Monkey
CytomX Therapeutics (CTMX) Holds Steady at $3.76 as Consolidation ContinuesRisk Reversal - newsline.com
CytomX Therapeutics to Present at Upcoming June Investor Conferences - The Manila Times
CytomX Therapeutics in June investor events at Jefferies, Goldman Sachs - Stock Titan
CTMX Stock Price, Quote & Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
Wolfe Research initiates CytomX stock with outperform rating By Investing.com - Investing.com Australia
Wolfe Research Initiates CytomX Therapeutics With Outperform Rating - Moomoo
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):